Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Huixing Zhou, Chunrui Li, Baijun Fang, Lingzhi Yan, Aijun Liu, Peiling Zhang, Yang Liu, Xiaoqi Qin, Huanxin Zhang, Wei Zhou, Hong-Hu Zhu, Leng Yun, Yin WU, Yi Wang, Wenming Chen, Guangzhong Yang

Blood (2025) 146 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2025-2271

Published: 2025

Journal Articles

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Huanxin Zhang, Yi Wang, Chengcheng Fu, Yanli Feng, Yang Liu, Jing Wang, Chunrui Li, Wenming Chen, Zhenyu Li

Blood (2025) 146 (Supplement 1): 2270.

https://doi.org/10.1182/blood-2025-2270

Published: 2025

Journal Articles

Clinical impact and prognostic implications of concurrent light-chain amyloidosis in patients with POEMS syndrome: A single-center retrospective study

Yuhan Bao, Di Wang, Peiling Zhang, Ning An, Xinran Wang, Qiuxia Yu, Yang Gao, Chunrui Li

Blood (2025) 146 (Supplement 1): 7502.

https://doi.org/10.1182/blood-2025-7502

Published: 2025

Journal Articles

Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial

Tingting Liu, Haiming Kou, Yu Hu, Chunrui Li, Liang Tang

Blood (2025) 146 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2025-1226

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Xiaozhe Li, Chengcheng Fu, Chunrui Li, Song Jin, Di Wang, Huixing Zhou, Jingjing Shang, Guangzhong Yang, Wenming Chen, Juan Li

Blood (2025) 146 (Supplement 1): 7588.

https://doi.org/10.1182/blood-2025-7588

Published: 2025

Journal Articles

Organ-based classification and risk-stratified outcomes in 568 east Asian patients with chronic active epstein-barr virus infection: A multicenter retrospective cohort study

Xinran Wang, Hui Luo, Di Wang, Peiling Zhang, Ning An, Qiuxia Yu, Yuhan Bao, Yang Gao, Chunrui Li

Blood (2025) 146 (Supplement 1): 564.

https://doi.org/10.1182/blood-2025-564

Published: 2025

Journal Articles

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

Yinqiang Zhang, Zhaozhao Chen, Yingying Li, Wei Xie, Chunrui Li, Heng Mei

Blood (2025) 146 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2025-4077

Published: 2025

Journal Articles

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Jing Li, Zhenyu Li, Chunrui Li, Pengcheng He, Jun Luo, Rong Fu, Liye Zhong, Hang Quach, Jay Hocking, Peter Presgrave, Xiaoyi Tang, Wen Zhang, Jinchao Gao, Luyin Ding, Peiqi Li, Hui Zhou, Peng Liu

Blood (2025) 146 (Supplement 1): 702.

https://doi.org/10.1182/blood-2025-702

Published: 2025

Journal Articles

Functional difference of CAR T-cells prepared from peripheral stem cell collections and peripheral lymphocyte collections

Xi Ming, Rubing Zheng, Jiaying Wu, Wanying Liu, delian Zhou, Sijia Yan, Chunrui Li, Xiaojian Zhu, Yi Xiao

Blood (2025) 146 (Supplement 1): 7705.

https://doi.org/10.1182/blood-2025-7705

Published: 2025

Journal Articles

Microbiota-derived 1,5-pentanediamine attenuates CD19 CAR-T function

Rubing Zheng, Xi Ming, delian Zhou, Jiaying Wu, Wanying Liu, Sijia Yan, Chunrui Li, Xiaojian Zhu, Yi Xiao

Blood (2025) 146 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2025-7619

Published: 2025

Journal Articles

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

Wanying Liu, Jiaying Wu, Xi Ming, Rubing Zheng, Sijia Yan, Chunrui Li, Xiaojian Zhu, Yi Xiao

Blood (2025) 146 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2025-7245

Published: 2025

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma

Mengmeng Pan, Di Wang, Jie Xu, Shiwei Jin, Yan Wang, Yi Tao, Yuanfang Liu, Wanyan Ouyang, Xiangqin Weng, Hongmei Yi, Yu Huang, Xinmei Cao, Shuhua Li, Fuyuan Zhang, Weiping Zhang, Chunrui Li, Jian-Qing Mi

Blood blood.2025030559.

https://doi.org/10.1182/blood.2025030559

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Su Shuai, Bin Xu, Chunrui Li, Di Wang, Xiwen Tong, Yi Zhu, Xia Mao, Min Xiao, Donghua Zhang

Blood (2024) 144 (Supplement 1): 7062.

https://doi.org/10.1182/blood-2024-204278

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab in Light Chain Amyloidosis: A Single-Center Retrospective Study

Xinran Wang, Ning An, Qiuxia Yu, Yuhan Bao, Peiling Zhang, Wei Mu, Chunrui Li, Di Wang, Xiaolu Long

Blood (2024) 144 (Supplement 1): 7833.

https://doi.org/10.1182/blood-2024-204637

Published: 2024

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Elucidating Structural Epitope Mapping and Soluble BCMA in the Microenvironment: Impact on Anti-BCMA CAR-T Cell Functionality

Wei Mu, Ning An, Qiuxia Yu, Guang Hu, Haolong Lin, Chunrui Li

Blood (2024) 144 (Supplement 1): 7174.

https://doi.org/10.1182/blood-2024-210020

Published: 2024

Journal Articles

Predictive Model for Infection Risk in CAR-T Therapy Patients

Ning An, Chunrui Li, Hui Luo, Xinran Wang, Di Wang, Peiling Zhang, Wei Mu, Qiuxia Yu, Yuhan Bao, Yang Gao

Blood (2024) 144 (Supplement 1): 7211.

https://doi.org/10.1182/blood-2024-204477

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Clinical impact and prognostic implications of concurrent light-chain amyloidosis in patients with POEMS syndrome: A single-center retrospective study

Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Organ-based classification and risk-stratified outcomes in 568 east Asian patients with chronic active epstein-barr virus infection: A multicenter retrospective cohort study

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Functional difference of CAR T-cells prepared from peripheral stem cell collections and peripheral lymphocyte collections

Microbiota-derived 1,5-pentanediamine attenuates CD19 CAR-T function

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Efficacy and Safety of Daratumumab in Light Chain Amyloidosis: A Single-Center Retrospective Study

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Elucidating Structural Epitope Mapping and Soluble BCMA in the Microenvironment: Impact on Anti-BCMA CAR-T Cell Functionality

Predictive Model for Infection Risk in CAR-T Therapy Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only